e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Jason Weatherald, Louise Bondeelle, Marie-Camille Chaumais, Christophe Guignabert, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Philippe Rousselot, Marc Humbert, Anne Bergeron, David Montani
Source:
Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Journal Issue:
October
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jason Weatherald, Louise Bondeelle, Marie-Camille Chaumais, Christophe Guignabert, Laurent Savale, Xavier Jaïs, Olivier Sitbon, Philippe Rousselot, Marc Humbert, Anne Bergeron, David Montani. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
The new challenge of CTD-ILD: from basic science to clinical setting
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders
Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Year: 2020
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Experience of using Janus kinase inhibitors in COVID-19
Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment
Year: 2021
A patient with a lazarus effect on tyrosine kinase inhibition
Source: Virtual Congress 2020 – Lung cancer grand round
Year: 2020
Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs
Source: Eur Respir J 2013; 42: 28-41
Year: 2013
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019
Year: 2019
Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
p38 MAPK inhibitors in COPD
Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung
Year: 2012
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008
Tyrosine kinase inhibition of human pulmonary fibroblast migration
Source: Eur Respir J 2005; 26: Suppl. 49, 101s
Year: 2005
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2004 - Pulmonary fibrosis - new insights
Year: 2004
Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Kinase inhibitors
Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD
Year: 2012
Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease
Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017
Year: 2017
Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis
Source: ERS Lung Science Conference 2020
Year: 2020
Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed
Source: Eur Respir J 2013; 41: 3-4
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept